Primary synovial sarcoma of kidney is an uncommon neoplasm, metastasizing most commonly to lung. Surgery and/or palliative chemotherapy for pulmonary metastases is commonly used to improve tumor control and survival. Stereotactic body radiotherapy (SBRT) is a relatively new approach to treat pulmonary metastasis, encouraged by the results of cranial and spinal stereotactic radiosurgery. The local control and toxicity profile of patients with pulmonary metastasis treated with SBRT are comparable to pulmonary metastatectomy. Furthermore, with advancement of imaging techniques, immobilization techniques, tumor-tracking techniques, and treatment planning and delivery system, SBRT can now be alternatively employed for the treatment of pulmonary metastasis as a comparable substitute to surgical resection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0973-1482.63551 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative immunohistochemical evaluation between primary and metastatic lesion in a feline osteosarcoma - A case report.
Heliyon
January 2025
Programa de Pós-Graduação em Medicina Veterinária - Clínica e Reprodução Animal, Universidade Federal Fluminense, Niterói, RJ, Brazil.
Feline primary bone tumors are rare. Still, osteosarcoma (OSA) composes almost 80 % of malignant bone tumors in cats, affecting mostly elder feline individuals. Many differences are observed between canine and feline OSA regarding radiographic image and tumoral behavior, especially metastasis development.
View Article and Find Full Text PDFDevelopment of a bacteria-nanosapper for the active delivery of ZIF-8 particles containing therapeutic genes for cancer immune therapy.
Acta Pharm Sin B
December 2024
School of Pharmacy, Institute of Hepatology and Metabolic Diseases, Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou 311121, China.
Specific tumor-targeted gene delivery remains an unsolved therapeutic issue due to aberrant vascularization in tumor microenvironment (TME). Some bacteria exhibit spontaneous chemotaxis toward the anaerobic and immune-suppressive TME, which makes them ideal natural vehicles for cancer gene therapy. Here, we conjugated ZIF-8 metal-organic frameworks encapsulating eukaryotic murine interleukin 2 () expression plasmid onto the surface of VNP20009, an attenuated strain with well-documented anti-cancer activity, and constructed a TME-targeted delivery system named /ZIF-8@.
View Article and Find Full Text PDFDiverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.
Oncol Lett
March 2025
Division of Chest Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan, ROC.
EGFR and ALK are key driver mutations in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors are recommended as the first-line treatment for advanced NSCLC with driving oncogenes because they have fewer side effects and provide better disease control than chemotherapy. The present retrospective analysis aimed to investigate how altered driver genes impact cancer outcomes and clinical presentation.
View Article and Find Full Text PDFEfficacy evaluation of prophylactic cranial irradiation for limited stage small‑cell lung cancer in the magnetic resonance imaging era: A meta‑analysis.
Oncol Lett
March 2025
Department of Radiotherapy, Sun Yat-sen University Cancer Center Gansu Hospital, Lanzhou, Gansu 730050, P.R. China.
The role of prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (LS-SCLC) remains controversial in the era of magnetic resonance imaging (MRI). The present study aimed to evaluate the effectiveness of PCI in the treatment of LS-SCLC in the era of MRI. The PubMed, EMBASE and Cochrane Library databases were searched from the time of database creation until May 24, 2023, to identify clinical studies that evaluated the effectiveness of PCI in patients with LS-SCLC in the MRI era.
View Article and Find Full Text PDFThe differences in the distribution characteristics and prognostic value of tumor-infiltrating T lymphocyte subsets between lung adenocarcinoma and lung squamous cell carcinoma.
Chin Clin Oncol
December 2024
Department of Oncology Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: The characteristics of tumor immune microenvironment are important factors affecting the efficacy of immunotherapy, and there are differences in the distribution of tumor-infiltrating lymphocyte (TIL) subsets in different types of tumors. This study aims to compare the distributions of cluster of differentiation (CD) 4+ and CD4+ T cell subsets of TILs and their clinical significance between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).
Methods: The tumor tissues of 78 LUAD and 56 LUSC patients who underwent surgery at The Second Affiliated Hospital of Zhengzhou University between October 2020 and October 2022 were collected, TIL level were detected by pathological observation, and the proportions of CD4+, CD4+ T cell subsets and CD4+/CD4+ ratio in TILs were detected by flow cytometry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!